GNT Pharma, which failed to progress its clinical pipeline amid global financial woes several years ago, aims to get back on its feet with the help of a new development strategy and improved regulations. The South Korean company's CEO sat down with PharmAsia News to talk about the first-in-class stroke therapy Neu2000 and what the company aims to achieve.
SEOUL - More often than not, major scientific discoveries are made by chance or accident, and this was how South Korean bioventure GNT Pharma Co. Ltd. began to develop the world’s first multi-targeted stroke therapy, Neu2000.
"One day, one of my students found that aspirin inhibits glutamate toxicity. It was hard to believe at first, but...